BUSINESS INSIGHTS

The Indian Pharmaceutical Market to 2011
1. Cipla 2. Ranbaxy 3. Nicholas Piramal
Sales Growth 2004-05 (%)

Competitive Dynamics between the 20 leading companies in India, 2005
22%
Abbott

20% 18%
FDC Aristo Torrent Sun Pharma

4. Sun Pharmaceuticals 5. Zydus Cadila 6. Dr. Reddy’s 7. Alkem

16% 14% 12% 10%
Alembic Dr. Reddy’s Lupin Micro Labs Alkem Ranbaxy Novartis USV

8% 6% 4%

Wockhardt

2% 0% -1% -2% -3% -4% 50 75
Pfizer

Sanofi Aventis

NPIL

Cipla GSK

8. Lupin 9. Aristo 10. Torrent

125

150

175

200

225

250

275

300

Sales, 2005 ($m)

Zydus Cadila

MNC

Indian Company

Note: Bubble size is proportionate to 2005 Market Share; NPIL= Nicholas Piramal

Your insight into

Strategic position Best practice strategies Mergers and acquisitions Therapeutic focus

The Indian Pharmaceutical Market to 2011 provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. although a shift in priorities has occurred with many companies increasing their investments in research capabilities and thus establishing themselves as development partners of choice with international companies. A surge in growth is expected to take place between 2006 and 2008. the Indian pharmaceutical industry was valued at $4. Figure 1.3% over year previous sales of $4. the Indian pharmaceutical is ranked among the lowest as per sales potential in 2005. Russia.000 15% 10% 100.000 0 U S Ja pa er n m an Fr y an ce G U K Sp ai n C hi na Br az il In di a R us si a Ita ly -10% Market growth 2004-05 (%) Market size ($m) Source: The Indian Pharmaceutical Market to 2011 “On a global perspective. 2005 300. Brazil.000 40% 35% 250. this report analyzes current and future therapeutic focus. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities..000 Sales ($m) • In 2005. sales growth.The Indian Pharmaceutical Market to 2011 Traditionally.. representing an increase of 8. • MNCs have a modest representation among the top 20 companies in the Indian pharmaceutical industry. US. enabling Indian pharma companies to experience high market growth.3% share. This report will help you to identify the critical success factors that have driven company growth.000 5% 0% -5% Sales growth (%) 200. GSK captured a 6. EU5.660m.304m. • The re-introduction of the patent regime in 2005 has forced many smaller Indian companies to exit the industry.. For each company. However.. As the market leader.” . while others have been forced to re-evaluate existing corporate strategies. attributable to the opportunities presented by contract research and manufacturing sourcing (CRAMS). The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams. the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. 50. • The Indian market has been associated with commodity generics. China and Japan. evaluate diversification opportunities and assess the future potential of each company’s R&D portfolio over the next five years. based on 5 year CAGRs (compound annual growth rates) over 2001-05. key pipeline products and future growth prospects. Key findings of the report.1: Comparison of pharmaceutical sales in the markets of India. illustrating the highly fragmented nature of the market.000 30% 25% 20% 150. the rate of pharmaceutical spending is expected to continue growing at a rapid pace.

CIS. growth strategies and organizational structure. the strongest performance was recorded by products indicated for the treatment of alimentary tract and metabolism related disorders.Key questions answered in this report • What are the challenges faced by pharmaceutical companies in the Indian market? Opportunities • Emerging markets of Latin America.660m 26% Alimentary Tract & Metabolism 4% 5% 6% Musculo -Skeletal System Dermatology • Evaluate how market share of leading companies. • Benchmark forecast performance of the leading players by using analysis of key products in major indications. opportunities and threats for the market leaders? • Which of the ten companies features the most promising R&D pipeline and how will this impact future growth? Threats • Re-introduction of patent regime in India • Growing competition from China in manufacturing • Competition from Indian companies within the domestic market Source: The Indian Pharmaceutical Market to 2011 “Cipla’s strategy to establish itself in the Indian and international markets has been primarily through continual investments in manufacturing facilities.230m. 9% Respiratory 1% Cancer $4.. 2005 CNS • Gain insights from the best practices of the top 10 Indian pharma companies. developing drugs in collaboration with third parties and forming manufacturing contracts with international generics companies. which accrued sales of $1.” . Cipla. • Identify which therapy areas offer the greatest opportunity by evaluating the therapeutic focus of the competition. weaknesses..4%. Nicholas Piramal. such as Ranbaxy.3: Sales performance of different therapeutic areas in the Indian market..” Top five reasons to order your copy today Figure 1. by reviewing detailed profiles of current and future drug portfolios.. Anti-infectives Cardiovascular 16% 8% 23% • Assess the pipeline strength of the top 10 Indian Pharma companies and identify future opportunities for growth. Middle East and Asia • Further development of drug delivery technologies • Increasing public-private partnerships with international not-for-profit initiatives • How has the re-introduction of patent regime affected Indian pharmaceutical companies? Weaknesses • Lack of international presence • Faltering performance in domestic market • Current strategies focused only on domestic market and organic growth Strengths • Strong foothold in the Indian market • Strong relations with Indian government • Established manufacturing agreements with major western companies • Established reputation in the global HIV/AIDS market CIPLA • What are the market shares for the ten leading Indian companies 2005? • Which of the top ten companies are out performing and under performing in the current market situation and why? • What are the major strengths. Women's health 2% Others Source: The Indian Pharmaceutical Market to 2011 “In 2005. Sun Pharma and Zydus Cadila will change over the next 5 years. representing a market share of 26.

Dr. Other than manufacturing. While Dr. Reddy’s Laboratories commanded 2..4% Source: The Indian Pharmaceutical Market to 2011 Order this report today to find out more. Germany accounted for 49.9% RoW 0. This represented an increase of 14.6% of sales in 2005. with an active presence across the pharmaceutical value chain in the development and manufacturing of generic and branded pharmaceuticals and bulk pharmaceutical ingredients..6% US 12. in over 60 markets including Europe. the US market accounted for 12. Betapharm. Dr.27: Dr. The company manufactures and markets APIs.3% India 26. with an established presence in the US. novel drug delivery systems (NDDS) and new drug discovery research (NDDR) in a range of research fields. Reddy’s has further expanded its capabilities through organic growth. Figure 2. followed by Eastern Europe which accounted for 10. Germany and Russia.Sample information from the report Chapter 2: Company Analysis Dr Reddy’s Overview Dr. positioning the company at number six with sales of $123m. Reddy’s has an extensive international presence. Dr.7% $123m Germany 49.4% over 2004 sales of $108m. finished dosages and biologics as well as diagnostic products. the company has also taken an active part in expanding its geographic presence through M&A.4% of sales. the US and Japan. In the same year. .6% of the Indian pharmaceutical market in 2005. Eastern Europe 10. 2005 Dr. Reddy’s sells and markets its products in more than 100 countries. The company derives most of its revenues from exports and its international acquisitions that accounted for an estimated 65% of total revenues in 2005. Reddy’s has three established R&D centers that focus on the development of generics. Reddy’s also possesses a subsidiary in the US. which is involved in drug discovery research focused on new molecular targets. Reddy US Therapeutics. Reddy’s geographic presence. Driven by the acquisition of the German pharmaceutical company.9% of sales.

Product Portfolio Analysis .SWOT analysis .Leading products in the Indian pharmaceutical market .Product Portfolio Analysis .Strategic Positioning .Company Overview .Corporate Strategy Zydus Cadila Company Overview Geographic Presence Product Portfolio Analysis .Corporate strategy Alkem Company Overview Geographic Presence Product Portfolio Analysis .SWOT analysis .The Indian Pharmaceutical Market to 2011 TABLE OF CONTENTS CHAPTER 1 : THE PHARMACEUTICAL MARKET ENVIRONMENT IN INDIA • Summary • Introduction • Pharmaceutical market environment in India .R&D Pipeline .SWOT analysis .Sales focus by therapy area .Sales focus by therapy area .Factors shaping the Indian pharmaceutical market CHAPTER 2 : COMPANY ANALYSIS • Summary • Introduction • Indian Market analysis by company • Cipla .Marketed Portfolio .Marketed Portfolio .Strategic Positioning .Marketed Portfolio .Geographic Presence .Geographic Presence .Performance of leading companies in the Indian market .Sales focus by therapy area .Corporate Strategy Dr.Corporate strategy - • - - • - - • - - • - - .Marketed Portfolio .Sales focus by therapy area .R&D pipeline Strategic Positioning .R&D pipeline Strategic positioning .Corporate Strategy • Nicholas Piramal .Sales focus by therapy area .SWOT analysis .Performance of Therapeutic Areas .R&D Pipeline Strategic Positioning .Company Overview Geographic Presence Product Portfolio Analysis .Pharmaceutical spending in the Indian market .Sales focus by therapy area .Company Overview .SWOT analysis .SWOT analysis .R&D Pipeline .Corporate Strategy • Ranbaxy .Sales focus by therapy area .Marketed portfolio .Corporate strategy Lupin Company overview Geographic analysis Product portfolio .Marketed portfolio analysis .R&D Pipeline .SWOT analysis .Geographic Presence .Marketed Portfolio .Product Portfolio Analysis .Corporate Strategy • Sun Pharmaceuticals .Strategic Positioning .Marketed Portfolio . Reddy’s Overview Geographic analysis Product portfolio analysis .Company Overview .SWOT analysis .R&D pipeline Strategic positioning .Sales focus by therapy area .R&D Pipeline Strategic Positioning .

Company overview .5: Breakdown of the Cipla’s revenues by therapy area.Contract Research and Manufacturing Sourcing (CRAMS) . EU5.R&D pipeline .2: Sales of leading pharmaceutical companies in India.R&D pipeline .4: Competitive Dynamics between the 20 leading companies in India.8: Breakdown of the Ranbaxy’s revenues by therapy area. 2001-05 Table 2.2: Comparison of pharmaceutical spending in the markets of India.4: Sales of leading Indian pharmaceutical companies.Marketed portfolio analysis .Sales focus by therapy area .Marketed portfolio analysis . 2004-5 Figure 2.1: Comparison of pharmaceutical sales in the markets of India.1: Breakdown of the Indian pharmaceutical market by therapy area. Russia. 2001-05 Table 1.12: Ranbaxy geographic presence.3: Sales performance of different therapeutic areas in the Indian market.10: Cipla’s SWOT Analysis Figure 2. 2004–05 Table 2.9: Leading brands in Ranbaxy’s marketed portfolio.Corporate strategy • Torrent . China and Japan.7: Cipla’s Commercial Agreements 2001-2007 Table 2.13: Leading brands in NPIL’s marketed portfolio.2011 .Increasing competition from other low cost manufacturing markets such as China . 2005 Figure 1. 2004–05 Aristo Company overview Geographic analysis Product portfolio .Strategic Positioning . 2006 Table 2.Value versus volume driven market .10: Ranbaxy's R&D product pipeline.11: Cipla’s future direction Figure 2.SWOT analysis . 2005 Figure 1. 2004–05 Table 2. US.Geographic analysis .Strategic Positioning . 2004-05 Table 2. and the US.9: Cipla therapeutic areas sales performance. 2005 Figure 1.6: Leading brands in Cipla’s marketed portfolio.Sales focus by therapy area .12: Breakdown of the Nicholas Piramal’s revenues by therapy area. CHAPTER 3: FUTURE OUTLOOK AND COMPETITIVE PRESSURES • Summary • Introduction • Competitive pressures being faced by the Indian companies .Corporate strategy . 2004-05 Table 1. EU5. 2005 Figure 1. 2005 Figure 2.7: Share of Indian companies by sales.3: Leading brands in the Indian market.Market saturation in the Indian market across major therapy areas .Contract Research and low cost clinical trials .SWOT analysis .Re-introduction of product patent regime in 2005 . 2005 Figure 2. 2001-2005 Table 2. Brazil.The Indian Pharmaceutical Market to 2011 LIST OF FIGURES (ABRIDGED) Figure 1.Stringent pricing controls on numerous essential medicines • Future Indian pharmaceutical growth models .Product portfolio .5: Competitive dynamics between leading brands in the Indian market.6: Factors shaping the Indian pharmaceutical market Figure 2.11: Ranbaxy’s Commercial Agreements 2001-2007 Table 2. 2001-05 Table 2. Figure 1. 2005 LIST OF TABLES (ABRIDGED) Table 1. 2004–05 Table 2.Contract Manufacturing .Company forecast sales for the period -2005.Mergers and acquisitions CHAPTER 4: APPENDIX • - .8: Cipla’s geographic presence.

. Access permitted for one individual only Site License 2995 4330 5750 Please invoice my company (please complete invoice address below) I would like to pay by bank transfer (email address required) Debit my credit/charge card: Amex Visa Mastercard Access permitted for every individual based at one location Company License 5600 8100 10795 Card No________________________________________________________________________ Expiry Date _________ / _________ Signature ______________________________ Global access for every individual member of staff at the company To ask a question about license types.. Email/Fax/Postal promotion Brochure Table of Contents Colleague Recommendation Trade Press My Account Manager Conference materials Website/web search Payor details Title: Mr/Mrs/Ms First Name: Email Job Title (Please use BLOCK CAPITALS) Last Name: 5 Recipient details (If different from Payor) Department Title: Mr/Mrs/Ms First Name: Email Job Title Department Address City Country Tel State/Province Post Code/ZIP Fax (Please use BLOCK CAPITALS) Last Name: Address City Country Tel Fax State/Province Post Code/ZIP Sign here to confirm your order: ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED .com Communications Feedback Please let us know if any of the following factors influenced your purchase. (Please use BLOCK CAPITALS) 1 Company details 3 ______________________________________________________ ______________________________________________________ Company name: ________________________________________________________ EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number: _____________________________________________________________________________________________ Hard Copy (extra £50/€75/$95) Please allow 28 days for delivery Interactivity (extra £50/€75/$95) Search.com I would like to order the following report. email: marketing@globalbusinessinsights.FAX BACK TO: +44 (0) 207 900 6688 or scan and e-mail to marketing@globalbusinessinsights.. customize & translate content Purchase Order Number (if required)_____________________________________ Please select a license type: GB£ EUR US$ 2 1495 2160 2875 Payment method Please indicate your preferred currency: GB£ EUR US$ 4 Single User (eCopy) Total order value is ____________________________ I will forward a check payable to Business Insights Limited..